Tagrisso granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
Decision based on LAURA Phase III trial results which extended median progression-free survival by more than three years.Tagrisso also granted Breakthrough Therapy Designation in US in this setting.AstraZeneca’s supplemental New Drug Application (sNDA) for Tagrisso (osimertinib) has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after chemoradiotherapy (CRT). If approved, Tagrisso will be indicated for EGFRm patients whose tumours have